Portal de Periódicos da CAPES

Clinical evaluation of a new hypolipidemic drug, CIBA 13,437-Su

1969; Elsevier BV; Volume: 10; Issue: 2 Linguagem: Inglês

10.1016/s0368-1319(69)80011-6

2212-1056

Gunther Hartmann, Genevieve M. Forster,

Lipoproteins and Cardiovascular Health

The first clinical trials with a new aryloxy-type of hypolipidemic compound, the tetralin-derivative CIBA 13,437-Su, are reported. Various hyperlipidemic syndromes were treated in a total of 88 patients for periods up to 22 months. With daily doses of 4–10 mg/kg, i.e. 300-600 mg per day, serum triglycerides and cholesterol were markedly lowered. The most pronounced effect was observed in hyperlipidemias of Types III, IV, and V of the Fredrickson-Lees classification. The pre-β-fraction appeared to be more readily lowered than the β-fraction, although the rather resistant hypercholesterolemia of Type II responded in all cases, yet to a lesser degree, and these patients received the higher doses. Slight transient increases in serum transaminases were observed in 7 out of 88 patients. The compound was very well tolerated subjectively. The results demonstrate that 13,437-Su is a very potent hypolipidemic agent.